Barry A. Borlaug, MD

Barry A. Borlaug, MD is a cardiologist in Rochester, Minnesota, affiliated with the Mayo Clinic.

Articles by Barry A. Borlaug, MD

Barry Borlaug, MD | Image Credit: Mayo Clinic

Updated HFmrEF Guidelines From HFSA Support Standard HFrEF Treatment

May 15th 2026

Barry Borlaug, MD, discusses his recent publication collecting existing evidence on HFmrEF to reflect current data regarding treatment and management.

Tirzepatide Affects Men and Women with HFpEF Equally, With Barry Borlaug, MD

ByBarry A. Borlaug, MD

October 8th 2025

A prespecified secondary analysis revealed no difference in male and female patients’ responses to tirzepatide in obesity-related HFpEF.

Expert Perspectives: Top News in Heart Failure from HFSA Annual Scientific Meeting 2025

ByViet Le, DMSc, PA-C,Stephen Greene, MD,Barry A. Borlaug, MD,Javed Butler, MD, MPH, MBA,Ahmad Masri, MD, MS,Petra Mamic, MD,Milind Desai, MD, MBA,Henri Roukoz, MD,Benjamin Hansen, MD,Ronald Witteles, MD,Justin Ezekowitz, MD

October 3rd 2025

This set of interviews collects perspectives from 11 leading clinicians in the heart failure field, cataloguing the biggest news from 2025.

Barry A. Borlaug, MD: Impact of Tirzepatide on Cardiorenal End-Organ Damage | Image Credit: Mayo Clinicn HFpEF

Barry A. Borlaug, MD: Impact of Tirzepatide on Cardiorenal End-Organ Damage in HFpEF

ByBarry A. Borlaug, MD,Connor Iapoce

November 17th 2024

Barry A. Borlaug, MD describes the beneficial effect of tirzepatide on circulatory pressure-volume overload and end-organ damage in patients with HFpEF and obesity.